FDA Launches Immediate Review of Clinical Trials Involving Cell Transfer to Hostile Countries
The U.S. Food and Drug Administration (FDA) this week announced an immediate review of new...
CRISPR
GRIT Biotechnology and Vitalgen BioPharma Partner on CRISPR-AaCas12bMAX Cell Therapies
China-based cell therapy specialists GRIT Biotechnology and Shanghai Vitalgen BioPharma Co., Ltd have entered into...
HuidaGene Receives FDA Clinical Clearance for HG202 in Neovascular AMD Treatment
China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced receiving clinical clearance from the US Food...
China Issues Ethical Guidelines for Human Genome Editing, Prohibits Germline Editing
China’s Ministry of Science and Technology (MOST) has issued the Ethical Guidelines for Human Genome...
HuidaGene and Synthego Form Strategic Partnership for CRISPR-Based Therapies
HuidaGene (Shanghai) Biotechnology Co., Ltd, a clinical-stage biotechnology company based in China, has entered into...
HuidaGene’s MECP2 Duplication Syndrome Therapy Earns Positive EMA Opinion
HuidaGene (Shanghai) Biotechnology Co., Ltd, a biotech company based in China, has announced that it...
ChinaGene Secures CDE Approval for ZVS101e Gene Therapy Targeting Retinitis Pigmentosa
Beijing-based ChinaGene Technology Co., Ltd. has announced that it has received tacit clinical approval from...
Danaher Corporation to Establish Northern China Headquarters in Beijing’s Changping District
The Changping District People’s Government of Beijing Municipality has entered into a strategic cooperation agreement...
FDA Approves Casgevy, the First CRISPR-Based Gene Editing Therapy for β-Thalassemia
Casgevy (exagamglogene autotemcel), the pioneering gene editing therapy based on CRISPR technology, has received approval...
Shanghai BDgene’s BD112 Earns Orphan Drug Designation from US FDA for Huntington’s Disease
Shanghai BDgene Technology Co., Ltd, a specialist in gene therapy, has announced that its drug...
Epigenic Therapeutics Secures $32 Million in Series A Funding for Gene Modulation Therapy
Epigenic Therapeutics, a Shanghai-based biotech company specializing in gene modulation therapy through epigenome regulation, has...
HuidaGene Strikes Licensing Deal with Kactus Biosystems for Gene Editing Enzyme hfCas12Max
China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced a licensing agreement with fellow Shanghai-based firm...
Shanghai BDgene Technology Receives US FDA Approval for HSV-1 Stromal Keratitis Gene Therapy
Gene therapy specialist Shanghai BDgene Technology Co., Ltd has announced receiving approval from the US...
HuidaGene Therapeutics Enhances CRISPR-Cas12f System with Higher Editing Efficiency
HuidaGene (Shanghai) Therapeutics Co., Ltd, a China-based biotechnology company, has made significant strides in the...
BDgene’s CRISPR-Cas9 Therapy BD111 Accepted for CDE Review
Shanghai BDgene Technology Co., Ltd has announced that a clinical trial filing for its BD111,...
CorrectSequence Therapeutics’ tBE Tech Wins USPTO Patent for Gene Editing
Shanghai-based gene editing firm CorrectSequence Therapeutics announced it has received a patent from the United...
GeneRulor Medical Technology Raises Funds for Gene Editing Diagnostics
China-based gene editing specialist ZhuHai GeneRulor Medical Technology Co., Ltd. reportedly raised “tens of millions”...
BDgene Advances CRISPR-Based BD111 for Herpes Keratitis with IND Filing
Shanghai BDgene Technology Co., Ltd has completed efficacy and preliminary safety studies for BD111, its...